Overview
A leading pharmaceutical company at your service
As an independent and privately held company, Upsher-Smith focuses
on product growth and innovation for both branded and branded-generic
pharmaceuticals.
Our evolution
In 1919, F. A. Upsher-Smith began processing digitalis drug products
to treat patients suffering from congestive heart failure.
Today, Upsher-Smith still produces cardiology products and
has expanded into the areas of neurology, dermatology, and
women’s
health.
Pursuing improved drug therapies to improve people’s
lives
Our perspective is not “more products” but the right
products that meet the needs of our customers. We promise to
provide reliable, affordable products that have a daily impact
on people’s lives.
Strategic vision
To become a leader in providing therapies that empower people
suffering from central nervous system (CNS) diseases to lead
healthy, productive lives.
Focus
Upsher-Smith is focusing within CNS on therapeutic areas with
significant unmet need including epilepsy, Parkinson’s
disease, and Alzheimer’s disease.
|
